NCT01069341View on ClinicalTrials.gov

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions

Rubeosis IridisProliferative Diabetic Retinopathy

Interventions

DRUG

Ranibizumab

Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.

Trial Locations (1)

07103

Njms / Umdnj, Newark

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Bhagat, Neelakshi, M.D., M.P.H.

INDIV

NCT01069341 - Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery | Biotech Hunter | Biotech Hunter